ICO
Closed:

Novel Highly Tumour-restricted Antigens and Antibodies for Cancer Therapy

Cumulus Oncology identifies and funds the progression of early-stage opportunities to develop novel differentiated anti-cancer therapies, with the aim of improving outcomes for cancer patients. They are interested in identifying and engaging with academics who have highly tumour-restricted antigens or monoclonal or multivalent antibodies that target them which have the potential for therapeutic activity in cancer.

Approaches of Interest:

  • Novel monoclonal antibodies, bi- and / or tri-specific antibodies that bind highly tumour-restricted antigens which ...

Opportunity types being sought:

  • Technology

  • Academic Researcher

  • Centre of Excellence

  • Research Project

  • Spinout Company

To see the full details and submit your response please register now.

Benefits of registration:

  • Receive updates on the latest industry calls
  • Quickly and easily respond to calls via your dashboard
  • Build your academic profile

Opportunity types being sought:

  • Technology

  • Academic Researcher

  • Centre of Excellence

  • Research Project

  • Spinout Company

An online matchmaking platform for university-industry collaboration. Learn More

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.